Trial Profile

Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liraglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms MAGNA VICTORIA

Most Recent Events

07 May 2022 Results determining involvement of GDF15/GFRAL pathway in body weight-reducing effects of liraglutide treatment from two MAGNA VICTORIA studies (NCT01761318 and NCT0266004) presented at The joint congress on obesity of the European Association of the Study of Obesity and the International Federation for the Surgery of Obesity and metabolic disorders-European Chapter
28 Mar 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com